HBV YMDD变异者采用阿德福韦和恩替卡韦治疗144周临床比较

目的 评价阿德福韦(ADV)和恩替卡韦(ETV)治疗慢性乙型肝炎HBV YMDD变异患者144周的疗效和安全性.方法 2005年6月至2007年6月在门诊和住院的经拉米夫定(LAM)治疗后出现HBV YMDD变异的慢性乙型肝炎患者120例,随机分为4组,A组单用ADV 10 mg/d治疗144周;B组采用ADV 10 ...     

恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周疗效观察

目的探讨恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周的临床疗效。方法应用恩替卡韦治疗HBV DNA阳性的34例慢性乙型肝炎患者和24例乙型肝炎肝硬化患者,观察96周。结果 34例慢性乙型肝炎患者治疗12周、24周、48周和96周时HBV DNA低于检测下限比率分别为61.76%（21/34）,82.35%（28/34）,94.12%（32/34）和94.12%（32/34,P〈0.05）;22例乙型肝炎肝硬化患者也分别为72.73%（16/22）,81.82%（18/22）,81.82%（18/22）和90.91%（20/22,P〈0.05）;治疗期间未发生与应用恩替卡韦相关的不良反应。结论恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化患者有明显的疗效,安全性较好。     

恩替卡韦与替比夫定对治疗HBeAg阳性慢性乙型肝炎患者疗效及预测因素分析

目的 观察恩替卡韦与替比夫定治疗HBeAg阳性慢性乙型肝炎（CHB）患者的疗效及预测因素分析. 方法 将159例HBeAg阳性的CHB患者分为恩替卡韦分组（ETV组,81例）和替比夫定组（LDT组,78例）.治疗72周后,观察两组的应答情况[生化学应答率（丙氨酸转氨酶转复率）、完全病毒学应答率（HBV-DNA阴转率）、血清学应答率（HBeAg阴转率及HBeAg血清学转换率）],并且分析在治疗24周HBV-DNA转阴情况对72周疗效的预测影响.结果 两组患者治疗后各时间段的生化学应答率比较均无统计学意义（P均＞0.05）.治疗4周后ETV组和LDT组的HBV-DNA值与治疗前比较差异均具有统计学意义（P均＜0.05）,且治疗24周后ETV组的HBV-DNA值明显低于LDT组（P＜0.05）,但治疗72周后比较两组患者的完全病毒学应答率比较差异不具有统计学意义（P均＞0.05）.治疗各时间点ETV组比LDT组有着更高的血清学应答率,但差异不具有统计学意义（P均＞0.05）.治疗24周HBV-DNA转阴（HBV-DNA＜3lg拷贝/ml）的患者,72周具有更高的生化学应答率及血清学应答率（P均＜0.05）.结论 恩替卡韦与替比夫定对治疗CHB具有很好的疗效及较低的耐药率和不良反应,恩替卡韦在早期抗HBV-DNA优于替比夫定片,且治疗24周的HBV-DNA水平可预测长期疗效.     

A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B

To evaluate the efficacy and safety of entecavir （ETV） in hepatitis Be antigen （HBeAg）-positive chronic hepatitis B （CriB） patients who had not received a nucleoside analogue and who had failed in lamivudine （LVD） therapy. METHODS： Sixty-one patients were divided into three groups. Forty-two patients who had not received a nucleoside analogue were randomized into two groups： group A （n = 21） received LVD 100 mg/d and group B （n -- 21） received ETV 0.5 mg/d. The remaing 19 patients treated with LVD （n = 19）, who switched to ETV 1.0 mg/d served as group C. All patients were treated for 48 wk. HBV DNA levels were measured with polimerase- chain-reaction （PCR） analysis. Liver function tests, HBV serology and safety assessments were also conducted. RESULTS： Significantly more patients in group B （52.1% and 71.4%） had undetectable HBV DNA levels than in groups A （35.8% and 38%; P 〈 0.0001） and C （10.6% and 21.1%, P 〈 0.0001） at wk 24 and 48, respectively. At wk 48, ALT levels were normalized in more patients in group B （85.7%） than in groups A （76.2%） and C （74%）. CONCLUSION： ETV had a significantly higher response rate than LVD in patients with HBeAg-positive CriB who had not previously received a nucleoside analogue; ETV can effectively inhibit the replication of HBV DNA and normalize the levels of ALT in refractory CriB patients treated with LVD; and ETV is safe in clinical application.     

Telbivudine： A new treatment for chronic hepatitis B

Three hundred and fifty million people worldwide are estimated to be chronically infected with hepatitis B virus. 15%-40% of these subjects will develop cirrhosis, liver failure or hepatocellular carcinoma during their life. The treatment of chronic hepatitis B has improved dramatically over the last decade merits to the advent of nucleoside/nucleotide analogues and the use of pegylated interferons. Approved drugs for chronic hepatitis B treatment include： standard interferon- alpha 2b, pegylated interferon-alpha 2a, lamivudine, adefovir dipivoxil, and entecavir. Unfortunately, these agents are not effective in all patients and are associated with distinct side effects. Interferons have numerous side effects and nucleoside or nucleotide analogues, which are well tolerated, need to be used for prolonged periods, even indefinitely. However, prolonged treatment with nucleoside or nucleotide analogues is associated with a high rate of resistance. Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B. In contrast to other nucleoside analogues, Telbivudine has not been associated with inhibition of mammalian DNA polymerase with mitochondrial toxicity. Telbivudine has demonstrated potent activity against hepatitis B with a significantly higher rate of response and superior viral suppression compared with lamivudine, the standard treatment. Telbivudine has been generally well tolerated, with a low adverse effect profile, and at its effective dose, no dose- limiting toxicity has been observed. Telbivudine is one of the most potent antiviral agents for chronic hepatitis B virus and was approved by the FDA in late 2006.     

恩替卡韦对失代偿期乙型肝炎肝硬化患者血清转化生长因子-β1的影响

目的：观察恩替卡韦对失代偿期乙型肝炎肝硬化患者血清转化生长因子-β1（ TGF-β1）的影响。方法80例失代偿期乙型肝炎肝硬化患者按数字表法随机分为对照组40例、观察组40例,对照组采用常规治疗,观察组在常规治疗的基础上加用恩替卡韦治疗,共治疗24周。测定患者肝功能、HBV DNA和血清TGF-β1。结果两组患者治疗后ALT、总胆红素、白蛋白均有明显改善（ t ＝6．724、13．306、3．064、4．172、2.924、3．172,均P＜0．05）,观察组改善更明显（t＝2．469、2．160、3．064,均P＜0．05）。观察组治疗后HBV DNA转阴率为90％,对照组HBV DNA转阴率为75％,两组转阴率差异有统计学意义（χ2＝4．82,P＜0．05）。两组治疗后血清TGF-β1均有明显降低（t＝6．842、8．062,均P＜0．01）,与对照组比较,观察组降低更明显（t＝3．178,P＜0．05）。结论恩替卡韦可明显减少失代偿期乙型肝炎肝硬化TGF-β1,减轻肝脏纤维化。     

恩替卡韦联合六味五灵片治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎的临床观察

目的探讨恩替韦卡（ETV）联合六味五灵片治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎的疗效和安全性。方法将124例乙型肝炎病毒e抗原阳性慢性乙型肝炎患者采用随机数字表法分为两组,分别采用ETV联合六味五灵片治疗和单纯ETV治疗,比较两组肝功能及病毒复制指标。结果观察组有效率91．94％,对照组有效率82．26％,两组差异有统计学意义（Ridit=32．251,P〈0．05）;治疗24周、48周,观察组HBVDNA低于对照组,差异有统计学意义（t=2．365、4．595,均P〈0．05）;治疗后,观察组ALT、AST下降程度显著大于对照组（t=78．512、62．145,均P〈0．05）;治疗后两组ALT复常率、总有效率和反跳率差异均有统计学意义（x^2=25．621、46．241、11．512,均P〈0．05）,HBVDNA和HBeAg阳性低于检测下限例数差异具有统计学意义（x^2=17．265、21．264,均P〈0．05）。结论恩替韦卡联合六味五灵片治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎能够减轻肝脏纤维化．并具有明显解毒和抗病毒作用。     

恩替卡韦治疗高病毒载量慢性乙型肝炎疗效观察

目的：观察恩替卡韦治疗慢性乙型肝炎高病毒载量的临床疗效。方法随机选择未经过抗病毒治疗的慢性乙型肝炎患者59例,分为治疗组和对照组。治疗组：恩替卡韦0．5 mg每日1次,对照组：拉米夫定100 mg每日1次,观察2组患者治疗后12周、24周、48周的HBVDNA及ALT下降及转阴情况。结果治疗组在治疗12周、24周、48周HBVDNA下降值分别为3．70±0．68,2．64±0．58,2．20±0．56;对照组下降值分别为4．16±1．02,3.27±1．23,3.24±1．12;2组比较差异有统计学意义（P＜0．05）。治疗组在治疗开始后12周、24周、48周HBVDNA转阴率分别为64．28％、82．14％、89．28％;对照组组分别为32．25％、58．06％、64．50％,2组比较差异有统计学意义（P＜0．05）。2组患者在治疗12周时ALT复常率比较差异无统计学意义（P＞0．05）,在24周、48周比较差异有统计学意义（P＜0.05）。结论恩替卡韦治疗慢乙肝高病毒载量疗效显著,耐药发生率低。     

替比夫定与恩替卡韦治疗HBeAg阳性慢性乙型肝炎4年随访观察

目的比较替比夫定(LdT)和恩替卡韦(ETV)治疗HBeAg阳性的CHB,哪一个能较早地实现有限疗程。方法 60例HBeAg阳性的CHB患者随机分为LdT组和ETV组。在服药后第12周、24周及以后每24周复查,直至治疗和随访结束(4年,192周),检测血清HBV DNA定量、HBV血清标志物、肝功能、血清肌酸激酶。观察两组192周治疗结束时应答率及持续应答率以及患者达到停药标准所需的时间及费用。结果 192周时LdT组和ETV组治疗结束时应答率及持续应答率为43.3%(13/30)vs 16.7%(5/30)、36.7%(11/30)vs 10.0%(3/30),差异有统计学意义(P<0.05)。达到停药标准LdT组平均治疗时间为167.2周,费用28 089.6元,而ETV组平均治疗时间为186.4周,费用50 887.2元。结论治疗HBeAg阳性的CHB患者,实现有限疗程LdT更具有优势。